Next 10 |
home / stock / ions / ions articles
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor for meta...
Biogen Inc (NASDAQ:BIIB) is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limeli...
Monday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with&...
Friday, FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplonte...
Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which...
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its holdings, with a significant sale of DraftKings Inc (NASDAQ:DKNG) shares an...
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling over $6.5 million worth of Tesla Inc (NASDAQ:TSLA) shares. This sale come...
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY) for two undisclosed early-sta...
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
2024-04-12 13:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-09 18:30:03 ET Wolfe Research analyst issues OUTPERFORM recommendation for IONS on April 9, 2024 04:39PM ET. IONS was trading at $42.83 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 3 -...
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome PR Newswire – Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful...